Drug (ID: DG01838) and It's Reported Resistant Information
Name
Aspirin CD3
Synonyms
Aspirin CD3; Acetylsalicylic acid-d3; 921943-73-9; Aspirin-d3; UNII-7F6Y89636M; Acetylsalicylic Acid;ASA; 2-(2,2,2-trideuterioacetyl)oxybenzoic acid; 7F6Y89636M; Trideuteriomethylaspirin; Benzoic acid, (acetyl-2,2,2-D3-oxy)-; [2H3]-Acetylsalicylic acid; 2-(Acetoxy-d3)benzoic acid; HY-14654S; MFCD09752106; CS-0214015; A935842; Acetylsalicylic acid-(methyl-d3), analytical standard; Q27268193
    Click to Show/Hide
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
Liver cancer [ICD-11: 2C12]
[1]
Target . NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
3
IsoSMILES
[2H]C([2H])([2H])C(=O)OC1=CC=CC=C1C(=O)O
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)/i1D3
InChIKey
BSYNRYMUTXBXSQ-FIBGUPNXSA-N
PubChem CID
12280114
DrugBank ID
DB00945
Type(s) of Resistant Mechanism of This Drug
  EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Liver cancer [ICD-11: 2C12]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: LMCD1 antisense RNA 1 (LMCD1-AS1) [1]
Molecule Alteration Down-regulation
Interaction
Resistant Disease Cholangiocarcinoma [ICD-11: 2C12.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Huh-7 cells Liver Homo sapiens (Human) CVCL_0336
HepG2 cells Liver Homo sapiens (Human) CVCL_0027
In Vivo Model Male BALB/c-nu/nu athymic nude mice model Mus musculus
Experiment for
Molecule Alteration
qRT-PCR; Western bloting analysis; Luciferase assay; Immunofluorescence assay; ChIP assay; Immunohistochemistry analysis
Experiment for
Drug Resistance
MTT assay
Mechanism Description Aspirin targets P4HA2 through inhibiting NF-kappa-B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.
References
Ref 1 Aspirin targets P4HA2 through inhibiting NF-kB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinomaEBioMedicine. 2019 Jul;45:168-180. doi: 10.1016/j.ebiom.2019.06.048. Epub 2019 Jul 2.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.